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World Hepatitis Day — July 28, 2019
World Hepatitis Day, observed each year on July 28, was 
established to raise awareness and promote understand-
ing of viral hepatitis around the world. The theme of 
this year’s World Hepatitis Day is “Invest in Eliminating 
Hepatitis,” underscoring the need to increase commitment 
for hepatitis response.  In 2015, an estimated 257 million 
persons were living with hepatitis B and 71 million with 
hepatitis C worldwide (1). 
Persons who inject drugs are at highest risk for hepatitis C 
virus (HCV) infection. Globally, an estimated 15.6 million 
persons aged 15–64 years inject drugs, 52% of whom are 
HCV-antibody positive (2). This issue of MMWR features 
a report on the progress in the country of Georgia toward 
prevention and detection of HCV infection, and linkage 
to treatment, of persons with HCV infection who inject 
drugs (3). Georgia’s hepatitis C elimination program, 
launched in 2015, was recently named the world’s first 
Centre of Excellence in Viral Hepatitis Elimination by 
the European Association for the Study of the Liver 
International Liver Foundation. Access to hepatitis C test-
ing and treatment for persons who inject drugs is critical 
to achieving elimination in countries where persons who 
inject drugs account for a significant proportion of HCV 
infection. Additional information and resources about viral 
hepatitis are available at https://www.cdc.gov/hepatitis.
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In April 2015, the country of Georgia, with a high preva-
lence of hepatitis C virus (HCV) infection (5.4% of the adult 
population, approximately 150,000 persons), embarked on 
the world’s first national elimination program (1,2). Nearly 
40% of these infections are attributed to injection drug use, 
and an estimated 2% of the adult population currently inject 
drugs, among the highest prevalence of injection drug use 
in the world (3,4). Since 2006, needle and syringe programs 
(NSPs) have been offering HCV antibody testing to persons 
who inject drugs and, since 2015, referring clients with positive 
test results to the national treatment program. This report sum-
marizes the results of these efforts. Following implementation 
of the elimination program, the number of HCV antibody 
